Elissavet Konstantelou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elissavet Konstantelou has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Aikaterini Kosma
Metaxa Cancer Hospital, Piraeus, Greece
1 shared publication- Anastasios Palamidas
Pneumonology Department Athens Medical Center Athens Greece
1 shared publication - Anna Kyriakoudi
Intensive Care Unit, 1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, Thoracic Diseases General Hospital of Athens ‘Sotiria’, 11527 Athens, Greece
1 shared publication Anna Ntokou
Metaxa Cancer Hospital, Piraeus, Greece
1 shared publication- Anne-Claude Tabet
UF de Cytogénétique, Hôpital Robert Debré, AP-HP, Paris, France
1 shared publication - Antonia Koutsoukou
National and Kapodistrian University of Athens, 11527 Athens, Greece
1 shared publication
Latest Publications
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1535
Percutaneous CT-guided thermal ablation of primary lung cancer
Background: Thermal ablation is a minimally invasive treatment for patients with inoperable localized NSCLC. Objective: This retrospective study was performed to evaluate the effectiveness and safety of thermal ablation in patients with NSCLC. Methods: Twenty-five patients with a biopsy-proven stage IA inoperable NSCLC were treated with microwave ablation (MWA) between January 2019 and January 2021. Staging was established by a positron emission tomography-computed tomography (PET-CT) prior to ablation. Study endpoints were local control rates at 1-year and 2-years, overall survival (OS), disease free survival (DFS), recurrence and complication rates. Treatment outcome evaluation was based on follow-up CT studies and PET-CT scans. Complications requiring immediate intervention were also recorded. Results: Twenty-five patients (M:F = 16:9; mean age 72.56±8.05) were treated with CT-guided MWA. The average size of the lesion was 2.01±0.63cm (95%CI: 1.74-2.27, range: 1.3-3 cm). No procedure-related mortality was recorded. The overall complication rate was 20%. Pneumothorax, local haemorrhage and low-grade fever were the most common complications with an incidence rate of 12%, 8% and 8% respectively. The average disease-free survival was 36.36 ± 2.59 months (95%CI 31.26-41.45, Kaplan-Meier) while the overall survival was 38.40 ± 2.00 months (95%CI: 34.46-42.33 Kaplan-Meier). One patient showed increasing soft tissue mass at the ablation site 6 months post-treatment and MWA was repeated. The 1-year and 2-years OS rates were 96% and 88% respectively, while the rates of local control were at 1-year and 2-years 88% and 84% respectively. Conclusion: MWA therapy is a promising and safe treatment option for early-stage NSCLC.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1535
Percutaneous CT-guided thermal ablation of primary lung cancer
Background: Thermal ablation is a minimally invasive treatment for patients with inoperable localized NSCLC. Objective: This retrospective study was performed to evaluate the effectiveness and safety of thermal ablation in patients with NSCLC. Methods: Twenty-five patients with a biopsy-proven stage IA inoperable NSCLC were treated with microwave ablation (MWA) between January 2019 and January 2021. Staging was established by a positron emission tomography-computed tomography (PET-CT) prior to ablation. Study endpoints were local control rates at 1-year and 2-years, overall survival (OS), disease free survival (DFS), recurrence and complication rates. Treatment outcome evaluation was based on follow-up CT studies and PET-CT scans. Complications requiring immediate intervention were also recorded. Results: Twenty-five patients (M:F = 16:9; mean age 72.56±8.05) were treated with CT-guided MWA. The average size of the lesion was 2.01±0.63cm (95%CI: 1.74-2.27, range: 1.3-3 cm). No procedure-related mortality was recorded. The overall complication rate was 20%. Pneumothorax, local haemorrhage and low-grade fever were the most common complications with an incidence rate of 12%, 8% and 8% respectively. The average disease-free survival was 36.36 ± 2.59 months (95%CI 31.26-41.45, Kaplan-Meier) while the overall survival was 38.40 ± 2.00 months (95%CI: 34.46-42.33 Kaplan-Meier). One patient showed increasing soft tissue mass at the ablation site 6 months post-treatment and MWA was repeated. The 1-year and 2-years OS rates were 96% and 88% respectively, while the rates of local control were at 1-year and 2-years 88% and 84% respectively. Conclusion: MWA therapy is a promising and safe treatment option for early-stage NSCLC.
- Open Access
- 16 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (16) , 1788
Extraosseous Plasmacytomas: A Radiologist’s Perspective—A Narrative Review of the Literature
Extraosseous plasmacytomas (EPs) are rare neoplasms originating from plasma cells, often associated with multiple myeloma. EPs are classified into three subtypes: extramedullary myeloma, solitary extramedullary plasmacytoma (SEP), and multiple solitary plasmacytomas. They can manifest in various anatomical sites, including the lung, mediastinum, breast, liver, pancreas, stomach, mesentery, kidney, small and large bowel, testis, and soft tissue. Despite their rarity, EPs present a diagnostic challenge due to their non-specific imaging appearances, which can mimic other neoplastic and inflammatory conditions. This review aims to describe the radiographic features of EPs in the chest, abdomen, and pelvis based on a thorough analysis of the existing literature. While imaging plays a crucial role in the detection and characterization of EPs, histological confirmation is necessary to differentiate them from other neoplastic entities. The review underscores the importance of considering EPs in the differential diagnosis, particularly in patients with a history of multiple myeloma. Understanding the imaging characteristics of EPs is essential for accurate diagnosis and appropriate management. Early imaging is crucial in these patients to exclude the possibility of EP, as timely diagnosis can significantly impact patient outcomes.
- 16 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (16) , 1788
Open AccessExtraosseous Plasmacytomas: A Radiologist’s Perspective—A Narrative Review of the Literature
Extraosseous plasmacytomas (EPs) are rare neoplasms originating from plasma cells, often associated with multiple myeloma. EPs are classified into three subtypes: extramedullary myeloma, solitary extramedullary plasmacytoma (SEP), and multiple solitary plasmacytomas. They can manifest in various anatomical sites, including the lung, mediastinum, breast, liver, pancreas, stomach, mesentery, kidney, small and large bowel, testis, and soft tissue. Despite their rarity, EPs present a diagnostic challenge due to their non-specific imaging appearances, which can mimic other neoplastic and inflammatory conditions. This review aims to describe the radiographic features of EPs in the chest, abdomen, and pelvis based on a thorough analysis of the existing literature. While imaging plays a crucial role in the detection and characterization of EPs, histological confirmation is necessary to differentiate them from other neoplastic entities. The review underscores the importance of considering EPs in the differential diagnosis, particularly in patients with a history of multiple myeloma. Understanding the imaging characteristics of EPs is essential for accurate diagnosis and appropriate management. Early imaging is crucial in these patients to exclude the possibility of EP, as timely diagnosis can significantly impact patient outcomes.
- Open Access
- 31 December 2021
- Published by MDPI AG in Diagnostics
- Vol. 12 (1) , 92
Weaning Failure in Critically Ill Patients Is Related to the Persistence of Sepsis Inflammation
Introduction: Septic patients undergoing mechanical ventilation (MV) often experience difficulty in weaning. Th aim of this study was to determine whether inflammatory biomarkers of sepsis could be indicative of the failure or success of spontaneous breathing trial (SBT) in these patients. Methods: Sixty-five patients on MV (42 septic and 23 intubated for other reasons) fulfilling the criteria for SBT were included in the study. Blood samples were collected right before, at the end of (30 min) and 24 h after the SBT. Serum inflammatory mediators associated with sepsis (IL-18, IL-18BP, TNF) were determined and correlated with the outcome of SBT. Results: A successful SBT was achieved in 45 patients (69.2%). Septic patients had a higher percentage of SBT failure as compared to non-septic patients (85% vs. 15%, p = 0.026), with an odds ratio for failing 4.5 times (OR = 4.5 95%CI: 1.16–17.68, p 0.022). IL-18 levels and the relative mRNA expression in serum were significantly higher in septic as compared to non-septic patients (p < 0.05). Sepsis was independently associated with higher serum IL-18 and TNF levels in two time-point GEE models (53–723, p = 0.023 and 0.3–64, p = 0.048, respectively). IL-18BP displayed independent negative association with rapid shallow breathing index (RSBI) (95% CI: −17.6 to −4, p = 0.002). Conclusion: Sustained increased levels of IL-18 and IL-18BP, acknowledged markers of sepsis, were found to be indicative of SBT failure in patients recovering from sepsis. Our results show that, although subclinical, remaining septic inflammation that sustaines for a long time complicates the weaning procedure. Biomarkers for the estimation of the septic burden and the right time for weaning are needed.
- 31 December 2021
- Published by MDPI AG in Diagnostics
- Vol. 12 (1) , 92
Open AccessWeaning Failure in Critically Ill Patients Is Related to the Persistence of Sepsis Inflammation
Introduction: Septic patients undergoing mechanical ventilation (MV) often experience difficulty in weaning. Th aim of this study was to determine whether inflammatory biomarkers of sepsis could be indicative of the failure or success of spontaneous breathing trial (SBT) in these patients. Methods: Sixty-five patients on MV (42 septic and 23 intubated for other reasons) fulfilling the criteria for SBT were included in the study. Blood samples were collected right before, at the end of (30 min) and 24 h after the SBT. Serum inflammatory mediators associated with sepsis (IL-18, IL-18BP, TNF) were determined and correlated with the outcome of SBT. Results: A successful SBT was achieved in 45 patients (69.2%). Septic patients had a higher percentage of SBT failure as compared to non-septic patients (85% vs. 15%, p = 0.026), with an odds ratio for failing 4.5 times (OR = 4.5 95%CI: 1.16–17.68, p 0.022). IL-18 levels and the relative mRNA expression in serum were significantly higher in septic as compared to non-septic patients (p < 0.05). Sepsis was independently associated with higher serum IL-18 and TNF levels in two time-point GEE models (53–723, p = 0.023 and 0.3–64, p = 0.048, respectively). IL-18BP displayed independent negative association with rapid shallow breathing index (RSBI) (95% CI: −17.6 to −4, p = 0.002). Conclusion: Sustained increased levels of IL-18 and IL-18BP, acknowledged markers of sepsis, were found to be indicative of SBT failure in patients recovering from sepsis. Our results show that, although subclinical, remaining septic inflammation that sustaines for a long time complicates the weaning procedure. Biomarkers for the estimation of the septic burden and the right time for weaning are needed.
- Open Access
- 6 July 2021
- Published by MDPI AG in Biosensors
- Vol. 11 (7) , 224
Clinical Application of the Novel Cell-Based Biosensor for the Ultra-Rapid Detection of the SARS-CoV-2 S1 Spike Protein Antigen: A Practical Approach
The availability of antigen tests for SARS-CoV-2 represents a major step for the mass surveillance of the incidence of infection, especially regarding COVID-19 asymptomatic and/or early-stage patients. Recently, we reported the development of a Bioelectric Recognition Assay-based biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus in just three minutes, with high sensitivity and selectivity. The working principle was established by measuring the change of the electric potential of membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody after attachment of the respective viral protein. In the present study, we applied the novel biosensor to patient-derived nasopharyngeal samples in a clinical set-up, with absolutely no sample pretreatment. More importantly, membrane-engineered cells were pre-immobilized in a proprietary biomatrix, thus enabling their long-term preservation prior to use as well as significantly increasing their ease-of-handle as test consumables. The plug-and-apply novel biosensor was able to detect the virus in positive samples with a 92.8% success rate compared to RT-PCR. No false negative results were recorded. These findings demonstrate the potential applicability of the biosensor for the early, routine mass screening of SARS-CoV-2 on a scale not yet realized.
- 6 July 2021
- Published by MDPI AG in Biosensors
- Vol. 11 (7) , 224
Open AccessClinical Application of the Novel Cell-Based Biosensor for the Ultra-Rapid Detection of the SARS-CoV-2 S1 Spike Protein Antigen: A Practical Approach
The availability of antigen tests for SARS-CoV-2 represents a major step for the mass surveillance of the incidence of infection, especially regarding COVID-19 asymptomatic and/or early-stage patients. Recently, we reported the development of a Bioelectric Recognition Assay-based biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus in just three minutes, with high sensitivity and selectivity. The working principle was established by measuring the change of the electric potential of membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody after attachment of the respective viral protein. In the present study, we applied the novel biosensor to patient-derived nasopharyngeal samples in a clinical set-up, with absolutely no sample pretreatment. More importantly, membrane-engineered cells were pre-immobilized in a proprietary biomatrix, thus enabling their long-term preservation prior to use as well as significantly increasing their ease-of-handle as test consumables. The plug-and-apply novel biosensor was able to detect the virus in positive samples with a 92.8% success rate compared to RT-PCR. No false negative results were recorded. These findings demonstrate the potential applicability of the biosensor for the early, routine mass screening of SARS-CoV-2 on a scale not yet realized.
- Open Access
- 2 September 2015
- Published by Springer Nature in BMC Medical Genetics
- Vol. 16 (1) , 77
Insertion of an extra copy of Xq22.2 into 1p36 results in functional duplication of the PLP1 gene in a girl with classical Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease (PMD) is an X-linked dysmyelinating disorder characterized by nystagmus, hypotonia, ataxia, progressive spasticity, and cognitive decline. PMD classically results from a duplication of a genomic segment encompassing the entire PLP1 gene. Since the PLP1 gene is located in Xq22, PMD affects mostly boys. Here we report the case of a girl with typical PMD. Copy number analysis of the PLP1 locus revealed a duplication of the entire gene and FISH analysis showed that the extra copy of the PLP1 gene was actually inserted in chromosome 1p36. This insertion of an additional copy of PLP1 in an autosome led to a functional duplication irrespective of the X-inactivation pattern. Subsequent overexpression of PLP1 was the cause of the PMD phenotype observed in this girl. Further sequencing of the breakpoint junction revealed a microhomology and thus suggested a replication based mechanism (such as FoSTeS or MMBIR). This case emphasizes the susceptibility of the PLP1 locus to complex rearrangement likely driven by the Xq22 local genomic architecture. In addition, careful consideration should be given to girls with classical PMD clinical features since they usually experience complex PLP1 genomic alteration with a distinct risk of inheritance.
- 2 September 2015
- Published by Springer Nature in BMC Medical Genetics
- Vol. 16 (1) , 77
Open AccessInsertion of an extra copy of Xq22.2 into 1p36 results in functional duplication of the PLP1 gene in a girl with classical Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease (PMD) is an X-linked dysmyelinating disorder characterized by nystagmus, hypotonia, ataxia, progressive spasticity, and cognitive decline. PMD classically results from a duplication of a genomic segment encompassing the entire PLP1 gene. Since the PLP1 gene is located in Xq22, PMD affects mostly boys. Here we report the case of a girl with typical PMD. Copy number analysis of the PLP1 locus revealed a duplication of the entire gene and FISH analysis showed that the extra copy of the PLP1 gene was actually inserted in chromosome 1p36. This insertion of an additional copy of PLP1 in an autosome led to a functional duplication irrespective of the X-inactivation pattern. Subsequent overexpression of PLP1 was the cause of the PMD phenotype observed in this girl. Further sequencing of the breakpoint junction revealed a microhomology and thus suggested a replication based mechanism (such as FoSTeS or MMBIR). This case emphasizes the susceptibility of the PLP1 locus to complex rearrangement likely driven by the Xq22 local genomic architecture. In addition, careful consideration should be given to girls with classical PMD clinical features since they usually experience complex PLP1 genomic alteration with a distinct risk of inheritance.